Preferred Label : Anti-CD73 Monoclonal Antibody JAB-BX102;
NCIt definition : A humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster
of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating
and antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody
JAB-BX102 targets and binds to CD73 on tumor cells, thereby inhibiting the activity
of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate
(AMP) to adenosine and the adenosine-mediated suppression of lymphocyte activity and
trafficking. This attenuates the adenosine-induced immunosuppression in the tumor
microenvironment (TME), increases the activity of cytotoxic T-lymphocytes (CTLs),
activates macrophages and reduces the activity of both myeloid-derived suppressor
cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect
on the immune system and enhancing the CTL-mediated immune response against cancer
cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to
the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types
and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable
nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression
within the TME.;
Molecule name : JAB BX102; JAB-BX102;
NCI Metathesaurus CUI : CL1778588;
Origin ID : C186370;
UMLS CUI : C5667054;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
